NCT06591793View on ClinicalTrials.gov

Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 2, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2029

Conditions
Usher Syndrome, Type 1B
Interventions
BIOLOGICAL

AAVB-081

Single subretinal administration

Trial Locations (3)

Unknown

RECRUITING

University of Campania Luigi Vanvitelli, Naples

RECRUITING

Moorfields Eye Hospital, London

RECRUITING

Retina Clinic London, London

Sponsors
All Listed Sponsors
lead

AAVantgarde Bio Srl

INDUSTRY

NCT06591793 - Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa | Biotech Hunter | Biotech Hunter